10.1200/JCO.2023.41.6_suppl.166 Journal of Clinical Oncology 41, no. 6_suppl (February 20, 2023) 166-166.
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study / Gennusa, V., Saieva, C., Lee-Ying, R.M., Nuzzo, P.V., Spinelli, G.P., Zanardi, E., Fotia, G., Rossetti, S., Valenca, L.B., Patrikidou, A., Andrade, L., Pereira Mestre, R., Fornarini, G., Procopio, G., Santini, D., Sweeney, C., Heng, D.Y.C., De Giorgi, U., Russo, A., Francini, E.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 41:(2023), pp. 166-166. [10.1200/JCO.2023.41.6_suppl.166]
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study
Francini, Edoardo
Conceptualization
2023
Abstract
10.1200/JCO.2023.41.6_suppl.166 Journal of Clinical Oncology 41, no. 6_suppl (February 20, 2023) 166-166.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
